41. Rheumatoid arthritis and the emergence of immuno-autonomics. (9th June 2019) Authors: Taylor, Peter C; Holman, Andrew J Journal: Rheumatology Issue: Volume 58:Number 12(2019) Page Start: 2079 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
42. Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis. (3rd December 2021) Authors: Uhrenholt, Line; Christensen, Robin; Dinesen, Wilfred K H; Liboriussen, Caroline H; Andersen, Stine S; Dreyer, Lene; Schlemmer, Annette; Hauge, Ellen-Margrethe; Skrubbeltrang, Conni; Taylor, Peter C; Kristensen, Salome Journal: Rheumatology Issue: Volume 61:Number 8(2022) Page Start: 3107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
43. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Issue 10271 (23rd January 2021) Authors: Humby, Frances; Durez, Patrick; Buch, Maya H; Lewis, Myles J; Rizvi, Hasan; Rivellese, Felice; Nerviani, Alessandra; Giorli, Giovanni; Mahto, Arti; Montecucco, Carlomaurizio; Lauwerys, Bernard; Ng, Nora; Ho, Pauline; Bombardieri, Michele; Romão, Vasco C; Verschueren, Patrick; Kelly, Stephen; Sain... Journal: Lancet Issue: Volume 397:Issue 10271(2021) Page Start: 305 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
44. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Issue 2 (27th November 2014) Authors: Keystone, Edward C; Taylor, Peter C; Drescher, Edit; Schlichting, Douglas E; Beattie, Scott D; Berclaz, Pierre-Yves; Lee, Chin H; Fidelus-Gort, Rosanne K; Luchi, Monica E; Rooney, Terence P; Macias, William L; Genovese, Mark C Journal: Annals of the rheumatic diseases Issue: Volume 74:Issue 2(2015) Page Start: 333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
45. Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. (June 2022) Authors: Fleischmann, Roy; Friedman, Alan; Drescher, Edit; Singhal, Atul; Cortes-Maisonet, Gregorio; Doan, Thao; Lu, Wenjing; Wang, Zailong; Nader, Ahmed; Housley, William; Cohen, Stanley; Taylor, Peter C; Blanco, Ricardo Journal: Lancet Issue: Volume 4:Number 6(2022) Page Start: e395 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
46. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Issue 3 (27th October 2021) Authors: Taylor, Peter C; Takeuchi, Tsutomu; Burmester, Gerd R; Durez, Patrick; Smolen, Josef S; Deberdt, Walter; Issa, Maher; Terres, Jorge Ross; Bello, Natalia; Winthrop, Kevin L Journal: Annals of the rheumatic diseases Issue: Volume 81:Issue 3(2022) Page Start: 335 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
47. Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial. Issue 10 (24th April 2019) Authors: Sweet, Kristen; Dasgupta, Bidisha; de Vries, Dick; Gourley, Ian; Hsu, Benjamin; Loza, Matthew J; Taylor, Peter C Journal: Annals of the rheumatic diseases Issue: Volume 78:Issue 10(2019) Page Start: 1439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
48. Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial. Issue 10 (October 2019) Authors: Sweet, Kristen; Dasgupta, Bidisha; de Vries, Dick; Gourley, Ian; Hsu, Benjamin; Loza, Matthew J; Taylor, Peter C Journal: Annals of the rheumatic diseases Issue: Volume 78:Issue 10(2019) Page Start: 1439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
49. Spondyloarthropathy: interleukin 23 and disease modification. Issue 9982 (23rd May 2015) Authors: Sherlock, Jonathan P; Taylor, Peter C; Buckley, Christopher D; Cua, Daniel J Journal: Lancet Issue: Volume 385:Issue 9982(2015) Page Start: 2017 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
50. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Issue 6 (16th June 2019) Authors: Humby, Frances; Lewis, Myles; Ramamoorthi, Nandhini; Hackney, Jason A; Barnes, Michael R; Bombardieri, Michele; Setiadi, A. Francesca; Kelly, Stephen; Bene, Fabiola; DiCicco, Maria; Riahi, Sudeh; Rocher, Vidalba; Ng, Nora; Lazarou, Ilias; Hands, Rebecca; van der Heijde, Désirée; Landewé, Robert B... Journal: Annals of the rheumatic diseases Issue: Volume 78:Issue 6(2019) Page Start: 761 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗